Esperion Therapeutics, Inc. (ESPR) Insider Trading
Over the last 3 months, ESPR insiders made 0 open-market buys and 3 sales, a net sale of -$102K (SEC Form 4). Over the last 6 months, 164 institutions increased and 95 reduced their position (13F).
Insider Activity
Sentiment
0/100
Buys (3m)
0
Sells (3m)
3
Net (3m)
-$102.4K
Insider trades by month Buys Sells
Jun
Jul
Sep
Dec
Jan
Mar
Context3-month price +13%Institutions accumulating (13F)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 1, 2026 | Fischer Seth H. Z.director | Grant | 79,873 | — |
| Jun 1, 2026 | CARROLL J MARTINdirector | Grant | 79,873 | — |
| Jun 1, 2026 | Hoffman Robert E.director | Grant | 79,873 | — |
| Jun 1, 2026 | Shepard Jaydirector | Grant | 79,873 | — |
| Jun 1, 2026 | THOMPSON JOHN CRAIGdirector | Grant | 79,873 | — |
| Mar 18, 2026 | Looker Benjaminofficer: Chief Legal Officer | Sell | 5,708 | $2.70 |
| Mar 18, 2026 | Koenig Sheldon L.director, officer: President and CEO | Sell | 25,578 | $2.72 |
| Mar 18, 2026 | Halladay Benjaminofficer: Chief Financial Officer | Sell | 6,424 | $2.71 |
| Mar 16, 2026 | Koenig Sheldon L.director, officer: President and CEO | Grant | 723,760 | — |
| Mar 16, 2026 | Halladay Benjaminofficer: Chief Financial Officer | Grant | 221,270 | $2.44 |
| Mar 16, 2026 | Looker Benjaminofficer: Chief Legal Officer | Grant | 300,840 | — |
| Mar 16, 2026 | Halladay Benjaminofficer: Chief Financial Officer | Grant | 247,430 | — |
| Mar 16, 2026 | Koenig Sheldon L.director, officer: President and CEO | Grant | 647,460 | $2.44 |
| Mar 16, 2026 | Looker Benjaminofficer: Chief Legal Officer | Grant | 269,230 | $2.44 |
| Jan 21, 2026 | Looker Benjaminofficer: General Counsel | Sell | 1,689 | $2.88 |
| Dec 18, 2025 | Koenig Sheldon L.director, officer: President and CEO | Sell | 48,244 | $3.67 |
| Dec 18, 2025 | Looker Benjaminofficer: General Counsel | Sell | 6,517 | $3.67 |
| Dec 18, 2025 | Halladay Benjaminofficer: Chief Financial Officer | Sell | 7,337 | $3.67 |
| Dec 8, 2025 | Harlow John B. Jr.officer: Chief Commercial Officer | Grant | 380,000 | $3.79 |
| Dec 8, 2025 | Harlow John B. Jr.officer: Chief Commercial Officer | Grant | 424,536 | — |
| Sep 18, 2025 | Halladay Benjaminofficer: Chief Financial Officer | Sell | 7,046 | $2.81 |
| Sep 18, 2025 | Looker Benjaminofficer: General Counsel | Sell | 6,267 | $2.80 |
| Sep 18, 2025 | Koenig Sheldon L.director, officer: President and CEO | Sell | 28,427 | $2.79 |
| Jul 18, 2025 | Halladay Benjaminofficer: Chief Financial Officer | Sell | 11 | $1.11 |
| Jul 18, 2025 | Looker Benjaminofficer: General Counsel | Sell | 1,304 | $1.13 |
| Jul 2, 2025 | THOMPSON JOHN CRAIGdirector | Grant | 40,000 | $1.00 |
| Jun 18, 2025 | Koenig Sheldon L.director, officer: President and CEO | Sell | 30,474 | $1.11 |
| Jun 18, 2025 | Looker Benjaminofficer: General Counsel | Sell | 6,422 | $1.15 |
| Jun 18, 2025 | Halladay Benjaminofficer: Chief Financial Officer | Sell | 7,229 | $1.15 |
| Jun 2, 2025 | CARROLL J MARTINdirector | Grant | 33,000 | — |
Source: ESPR SEC Form 4 filings, latest Jun 1, 2026. For informational purposes only — not investment advice.
Institutional activity (13F)
How institutions changed their ESPR positions over the last 6 months (SEC Form 13F).
Increased
164
New positions
69
Reduced
95
Sold out
58
Largest moves
| Institution | Action | Shares | Filed |
|---|---|---|---|
| BLACKROCK, INC. | Increased | 17.9M | May 13, 2026 |
| BLACKROCK, INC. | Increased | 17.7M | Feb 12, 2026 |
| WASATCH ADVISORS LP | Increased | 15.8M | Apr 21, 2026 |
| VANGUARD GROUP INC | Increased | 14.9M | Jan 29, 2026 |
| TWO SEAS CAPITAL LP | Increased | 11.9M | Feb 11, 2026 |
| TWO SEAS CAPITAL LP | Reduced | 11.4M | May 15, 2026 |
| ORBIMED ADVISORS LLC | Increased | 10.6M | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 10.4M | May 15, 2026 |
| TWO SIGMA INVESTMENTS, LP | Increased | 9.5M | May 15, 2026 |
| WASATCH ADVISORS LP | Increased | 9.4M | Feb 12, 2026 |
| MARSHALL WACE, LLP | Increased | 7.1M | May 15, 2026 |
| STATE STREET CORP | Increased | 7.1M | May 15, 2026 |
| D. E. SHAW & CO., INC. | Increased | 6.9M | Feb 17, 2026 |
| D. E. SHAW & CO., INC. | Reduced | 6.5M | May 15, 2026 |
| ORBIMED ADVISORS LLC | New Position | 6.0M | Feb 17, 2026 |
Source: SEC Form 13F filings. For informational purposes only — not investment advice.